NYSE - Nasdaq Real Time Price USD

Novo Nordisk A/S (NVO)

66.52

+2.15

+(3.34%)

As of 12:14:09 PM EDT. Market Open.

Novo Nordisk Shares Dip 3% on Sudden CEO Transition Announcement

NVO stock declines 3% as the company announces that Lars Fruergaard Jorgensen will be stepping down as the CEO.

Zacks 1 hour ago

NVO
+3.34%

LLY
The Zacks Analyst Blog Highlights Bayer, Novo Nordisk, GSK, Merck and AbbVie

Bayer, Novo Nordisk, GSK, Merck and AbbVie are part of the Zacks top Analyst Blog.

Zacks 2 hours ago

ABBV

BAYN.DE

NVO
+3.34%
Novo Nordisk (NVO) Slides After CEO Departure; Analyst Flags Deeper Strategic Concerns

Shares fall nearly 4% as BMO warns leadership change won't fix core issues

GuruFocus.com 3 hours ago

NVO
+3.34%

LLY
Novo Nordisk’s CEO to step down as weight loss market share plummets

Novo Nordisk stated that replacing Jørgensen is "in the best interests of the company and its shareholders".

Pharmaceutical Technology 4 hours ago

LLY

NVO
+3.34%
Charter to combine with Cox, Take-Two reports mixed Q4 results: Morning Buzz

The major averages were little changed near noon following the release of downbeat consumer sentiment data and as April housing starts came in slightly below consensus estimates. Investors continue to weigh potentially easing trade tensions as well. Meanwhile, President Trump said in a post on Truth Social that Republican lawmakers “must unite” to pass his “beautiful” tax bill. Looking to commodities, gold prices are slipping after yesterday’s rebound, while oil is up fractionally, keeping the c

TipRanks 2 days ago

MSFT

NETTF

NTES
Why Viking Therapeutics Stock Bumped 3% Higher Today

Viking is pushing hard in its development of a weight-loss drug. A major C-suite change at a potential competitor was a key factor behind the rise of Viking Therapeutics (NASDAQ: VKTX) stock on Friday, which closed the trading session 3% higher. This is the Denmark-based pharmaceutical company that vaulted to prominence earlier this decade when its Wegovy became the first GLP-1 drug approved for obesity by the U.S. Food and Drug Administration (FDA).

Motley Fool 2 days ago

VKTX

NVO
+3.34%
Can a new CEO fix Novo Nordisk's problems? This analyst says no.

Novo Nordisk (NVO) stock fell after announcing that CEO Lars Fruergaard Jørgensen will step down. BMO Capital Markets managing director of biopharma equity research Evan Seigerman joins Market Domination with Josh Lipton and Bullseye American Ingenuity Fund portfolio manager Adam Johnson to discuss the surprise C-suite change. To watch more expert insights and analysis on the latest market action, check out more Market Domination here.

Yahoo Finance Video 2 days ago

NONOF

NVO
+3.34%
Analysis-Novo Nordisk should look to the US for its next CEO, analysts say

(Reuters) -As Denmark's Novo Nordisk shops for its next CEO to replace Lars Fruergaard Jorgensen, it should look across the Atlantic for a leader deeply entrenched in the United States, by far its largest market, analysts told Reuters. Novo, which manufactures the popular weight-loss drug Wegovy, said on Friday its current CEO will step down over concerns the company is losing its first-mover advantage in the highly competitive obesity drug market. Financial analysts Reuters spoke with said an American may be better placed to deal with a Trump administration, which is rewriting the rules on pharmaceutical trade, manufacturing, regulation and drug pricing.

Reuters 2 days ago

NVO
+3.34%

LLY
Novo Nordisk announces CEO transition as share price slips

After nearly tripling the company’s value, CEO Lars Fruergaard Jørgensen is preparing to exit amid boardroom shifts.

FastCompany 2 days ago

NVO
+3.34%
From insulin to Ozempic, history of Novo Nordisk's CEOs

Jorgensen, who joined in 2017, has had the shortest tenure of all. Danish couple August and Marie Krogh founded Nordsik Insulinlaboratorium in 1923 and commercialized the production of insulin. The company competed with Novo Terapeutisk Laboratorium, which was founded by brothers Harald and Thorvald Pedersen, until the two merged in 1989.

Reuters 2 days ago

NVO
+3.34%

LLY
Novo Nordisk CEO Exit After Massive Sell-Off Hits Shares

Novo Nordisk Stock Tanks, CEO on Way Out

GuruFocus.com 2 days ago

NVO
+3.34%
Galaxy Digital on the Nasdaq, Novo ousts CEO, Virgin Galactic

Yahoo Finance host Josh Lipton tracks today's top moving stocks and biggest market stories in this Market Minute, including Galaxy Digital's (GLXY) debut on the Nasdaq, Eli Lilly (LLY) getting a lift after Novo Nordisk (NVO) pushed out its CEO Lars Fruergaard Jørgensen, and Virgin Galactic (SPCE) forecasting passenger space flights in the fall of 2026. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.

Yahoo Finance Video 2 days ago

GLXY

LLY

SPCE
Stocks to Watch Friday: Charter, Novo Nordisk, Applied Materials

↗️ Charter Communications (CHTR): The company agreed to buy closely held rival Cox Communications for $21.9 billion, bringing together two of the biggest broadband and cable operators in the U.S. Shares in Charter rose about 1%.

The Wall Street Journal 2 days ago

CHTR

CFRHF

CFRUY
European Equities Close Higher in Friday Trading; Novo Nordisk CEO to Step Down

The European stock markets closed higher in Friday trading as the Stoxx Europe 600 gained 0.28%, Ger

PREMIUM
MT Newswires 2 days ago

HSBC

NVO
+3.34%
Top Midday Stories: Novo Nordisk CEO Stepping Down; Charter, Cox to Merge in $34.5 Billion Deal

All three major US stock indexes hovered around flat in late-morning trading Friday as a weaker-than

PREMIUM
MT Newswires 3 days ago

NVO
+3.34%

NVDA

BA
Novo Nordisk CEO to Step Down Amid Market Challenges

Novo Nordisk (NVO) shares fell intraday Friday after the Danish drugmaker said its chief executive,

PREMIUM
MT Newswires 3 days ago

NVO
+3.34%
Why Novo Nordisk Stock Just Slipped

Investors may get a second bite at the apple, and a second chance to buy this GLP-1 drug leader at a discount price.

Motley Fool 3 days ago

NVO
+3.34%
Novo Nordisk Sheds 3% After Ousting CEO As Eli Lilly Rivalry Slams Stock Price

Novo Nordisk said Friday it will replace its CEO, citing a sharp tumble for Novo shares amid growing competition.

Investor's Business Daily 3 days ago

VKTX

LLY

AMGN
Novo Nordisk Boots CEO After Stock Falls 50%. It’s an Unusual Move for the Wegovy Drugmaker.

It was a ‘mutual agreement,’ Novo says in a statement. A search for Fruergaard Jørgensen’s successor is ongoing.

Barrons.com 3 days ago

NVO
+3.34%

LLY
Ozempic boss sacked after falling behind in weight-loss race

The boss of the drugs giant Novo Nordisk has been sacked after falling behind in the global race to develop weight-loss medication.

The Telegraph 3 days ago

NVO
+3.34%

LLY

Performance Overview

Return	NVO	OMX Copenhagen 25 Index (^OMXC25)
YTD	-21.16%	-1.40%
1-Year	-48.56%	-11.68%
3-Year	+33.76%	+8.89%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Novo Nordisk A/S (NVO)

Novo Nordisk Shares Dip 3% on Sudden CEO Transition Announcement

The Zacks Analyst Blog Highlights Bayer, Novo Nordisk, GSK, Merck and AbbVie

Novo Nordisk (NVO) Slides After CEO Departure; Analyst Flags Deeper Strategic Concerns

Novo Nordisk’s CEO to step down as weight loss market share plummets

Charter to combine with Cox, Take-Two reports mixed Q4 results: Morning Buzz

Why Viking Therapeutics Stock Bumped 3% Higher Today

Can a new CEO fix Novo Nordisk's problems? This analyst says no.

Analysis-Novo Nordisk should look to the US for its next CEO, analysts say

Novo Nordisk announces CEO transition as share price slips

From insulin to Ozempic, history of Novo Nordisk's CEOs

Novo Nordisk CEO Exit After Massive Sell-Off Hits Shares

Galaxy Digital on the Nasdaq, Novo ousts CEO, Virgin Galactic

Stocks to Watch Friday: Charter, Novo Nordisk, Applied Materials

European Equities Close Higher in Friday Trading; Novo Nordisk CEO to Step Down

Top Midday Stories: Novo Nordisk CEO Stepping Down; Charter, Cox to Merge in $34.5 Billion Deal

Novo Nordisk CEO to Step Down Amid Market Challenges

Why Novo Nordisk Stock Just Slipped

Novo Nordisk Sheds 3% After Ousting CEO As Eli Lilly Rivalry Slams Stock Price

Novo Nordisk Boots CEO After Stock Falls 50%. It’s an Unusual Move for the Wegovy Drugmaker.

Ozempic boss sacked after falling behind in weight-loss race

Performance Overview